Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Genmab A (GNMSF) Cost of Revenue (2024 - 2025)

Historic Cost of Revenue for Genmab A (GNMSF) over the last 2 years, with Q4 2025 value amounting to -$157.0 million.

  • Genmab A's Cost of Revenue fell 42708.28% to -$157.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $238.0, marking a year-over-year decrease of 9999.98%. This contributed to the annual value of $238.0 for FY2025, which is 9999.98% down from last year.
  • Latest data reveals that Genmab A reported Cost of Revenue of -$157.0 million as of Q4 2025, which was down 42708.28% from $58.0 million recorded in Q3 2025.
  • Over the past 5 years, Genmab A's Cost of Revenue peaked at $58.0 million during Q3 2025, and registered a low of -$157.0 million during Q4 2025.